Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
105 shown of 8,197 total abstracts
  1. Abstract 96862026-04-03 · 16:00 CT · S406
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-525 study)
    C. Saura, M.C. Garassino · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  2. Abstract 95982026-04-05 · 16:00 CT · S100A
    CheckMate-472: Opdivo (nivolumab) 2L in metastatic melanoma
    G. Curigliano, S. Tolaney, H. Rugo, et al. · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  3. Abstract 100322026-04-05 · 13:30 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-693
    J. Brahmer, T. Mok · Massachusetts General Hospital
    Oral Abstract SessionMelanoma📄🖼️🎬
  4. Abstract 100822026-04-02 · 21:30 CT · Hall B1
    KEYNOTE-599: Keytruda (pembrolizumab) 3L+ in metastatic melanoma
    R. Herbst, L. Paz-Ares, C. Saura, et al. · Stanford Cancer Institute
    Oral Abstract SessionMelanoma📄🖼️🎬
  5. Abstract 101702026-04-02 · 13:30 CT · E450
    Long-term follow-up of Keytruda 2L for metastatic melanoma: KEYNOTE-966
    S. Peters, J. Brahmer, G. Curigliano, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionMelanoma📄🖼️
  6. Abstract 102462026-04-01 · 15:15 CT · Arie Crown Theater
    Long-term follow-up of Opdivo neoadjuvant for metastatic melanoma: CheckMate-158
    M.C. Garassino, T. Mok, S. Tolaney · National Cancer Center Japan
    Poster SessionMelanoma📄🖼️
  7. Abstract 97592026-04-04 · 20:45 CT · S406
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-346 study)
    F. Andre, E. Winer · Royal Marsden Hospital
    Oral Abstract SessionMelanoma📄🖼️🎬
  8. Abstract 99562026-04-02 · 19:15 CT · Hall B1
    CheckMate-498: Opdivo (nivolumab) neoadjuvant in metastatic melanoma
    G. Curigliano, S. Antonia · Princess Margaret Cancer Centre
    Oral Abstract SessionMelanoma📄🖼️🎬
  9. Abstract 100932026-04-03 · 18:15 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-92 study)
    E. Winer, J. Brahmer, R. Herbst, et al. · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  10. Abstract 100092026-04-01 · 15:45 CT · S100A
    CheckMate-81: Opdivo (nivolumab) neoadjuvant in metastatic melanoma
    S. Antonia, J. Brahmer, C. Saura · Karolinska Institute
    Poster Discussion SessionMelanoma📄🖼️
  11. Abstract 97492026-04-04 · 15:45 CT · E450
    Long-term follow-up of Keytruda 1L for metastatic melanoma: KEYNOTE-4
    C. Saura, A. Spira, H. Rugo, et al. · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  12. Abstract 99102026-04-01 · 13:00 CT · Arie Crown Theater
    CheckMate-399: Opdivo (nivolumab) maintenance in metastatic melanoma
    H. Borghaei, L. Paz-Ares, C. Saura, et al. · University of Chicago
    Poster Discussion SessionMelanoma📄🖼️
  13. Abstract e120122026-04-05 · 20:15 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-504
    S. Modi, F. Andre, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Publication OnlyMelanoma📄🖼️
  14. Abstract 102782026-04-01 · 19:15 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-732
    H. Borghaei, G. Curigliano · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  15. Abstract 104382026-04-02 · 21:45 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    S. Peters, M. Reck, S. Tolaney, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionMelanoma📄🖼️
  16. Abstract 103952026-04-01 · 16:00 CT · Arie Crown Theater
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    M. Reck, S. Modi, S. Antonia, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionMelanoma📄🖼️
  17. Abstract 98002026-04-03 · 15:30 CT · S406
    Long-term follow-up of Keytruda 2L for metastatic melanoma: KEYNOTE-334
    S. Modi, C. Saura, M.C. Garassino, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionMelanoma📄🖼️
  18. Abstract 103732026-04-03 · 18:00 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    J. Cortes, P. Schmid · Dana-Farber Cancer Institute
    Poster Discussion SessionMelanoma📄🖼️
  19. Abstract 102292026-04-03 · 15:45 CT · Arie Crown Theater
    CheckMate-545: Opdivo (nivolumab) 1L in metastatic melanoma
    S. Peters, F. Andre, G. Curigliano · University of Chicago
    Poster Discussion SessionMelanoma📄🖼️
  20. Abstract LBA4019LBA2026-04-05 · 16:00 CT · Arie Crown Theater
    KEYNOTE-704: Keytruda (pembrolizumab) maintenance in metastatic melanoma
    S. Peters, L. Paz-Ares, N. Rizvi · Johns Hopkins Kimmel Cancer Center
    Plenary SessionMelanoma📄🖼️
  21. Abstract 98352026-04-03 · 14:15 CT · S100A
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-701
    S. Antonia, R. Herbst, M.C. Garassino · Massachusetts General Hospital
    Poster Discussion SessionMelanoma📄🖼️
  22. Abstract 101192026-04-04 · 21:45 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
    S. Tolaney, C. Robert, C. Saura, et al. · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  23. Abstract 95932026-04-03 · 18:15 CT · Arie Crown Theater
    Long-term follow-up of Opdivo adjuvant for metastatic melanoma: CheckMate-176
    F. Andre, S. Antonia, E. Winer, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  24. Abstract 96432026-04-05 · 19:45 CT · S100A
    KEYNOTE-137: Keytruda (pembrolizumab) maintenance in metastatic melanoma
    H. Borghaei, J. Brahmer, C. Saura, et al. · Massachusetts General Hospital
    Poster Discussion SessionMelanoma📄🖼️
  25. Abstract 97182026-04-01 · 21:30 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-423 study)
    J. Cortes, P. Schmid, A. Spira, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionMelanoma📄🖼️
  26. Abstract 101362026-04-01 · 13:30 CT · Arie Crown Theater
    CheckMate-238: Opdivo (nivolumab) 1L in metastatic melanoma
    C. Robert, E. Winer, H. Borghaei, et al. · Princess Margaret Cancer Centre
    Poster SessionMelanoma📄🖼️
  27. Abstract 101242026-04-03 · 20:00 CT · S100A
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-610 study)
    H. Rugo, M.C. Garassino · Princess Margaret Cancer Centre
    Poster Discussion SessionMelanoma📄🖼️
  28. Abstract 101102026-04-05 · 20:15 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-341
    H. Borghaei, J. Cortes · Chinese University of Hong Kong
    Poster SessionMelanoma📄🖼️
  29. Abstract 96002026-04-04 · 14:30 CT · S406
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-731
    J. Cortes, S. Antonia, C. Saura · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  30. Abstract 104012026-04-03 · 14:30 CT · E450
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-587 study)
    T. Mok, M.C. Garassino, C. Saura · Stanford Cancer Institute
    Poster SessionMelanoma📄🖼️
  31. Abstract 99762026-04-05 · 13:15 CT · S100A
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-1 study)
    M.C. Garassino, A. Spira, H. Borghaei · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionMelanoma📄🖼️
  32. Abstract 96412026-04-03 · 21:30 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-250 study)
    C. Saura, M. Krop, S. Modi, et al. · Royal Marsden Hospital
    Poster SessionMelanoma📄🖼️
  33. Abstract 95432026-04-04 · 14:15 CT · Hall B1
    Long-term follow-up of Opdivo 1L for metastatic melanoma: CheckMate-562
    R. Herbst, S. Modi, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  34. Abstract 101002026-04-05 · 20:45 CT · S100A
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-225 study)
    G. Curigliano, P. Schmid · Cleveland Clinic
    Poster SessionMelanoma📄🖼️
  35. Abstract 95022026-04-05 · 20:45 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-192 study)
    J. Brahmer, R. Herbst · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  36. Abstract 97062026-04-03 · 20:00 CT · S100A
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-955
    J. Brahmer, S. Modi, A. Spira, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionMelanoma📄🖼️
  37. Abstract 100322026-04-02 · 14:15 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-540
    C. Robert, F. Andre, J. Brahmer, et al. · Stanford Cancer Institute
    Poster Discussion SessionMelanoma📄🖼️
  38. Abstract 102072026-04-01 · 18:30 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-361
    J. Brahmer, S. Peters, R. Herbst · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  39. Abstract 101822026-04-01 · 14:45 CT · Hall B1
    CheckMate-754: Opdivo (nivolumab) maintenance in metastatic melanoma
    S. Tolaney, F. Andre, H. Borghaei · Dana-Farber Cancer Institute
    Poster SessionMelanoma📄🖼️
  40. Abstract 103092026-04-02 · 18:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-447 study)
    H. Borghaei, C. Saura, M. Reck, et al. · MD Anderson Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  41. Abstract 103942026-04-02 · 13:00 CT · S406
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-105 study)
    C. Robert, S. Antonia, C. Saura · Massachusetts General Hospital
    Poster SessionMelanoma📄🖼️
  42. Abstract 98022026-04-03 · 13:30 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-513
    C. Robert, S. Tolaney · University of Chicago
    Poster Discussion SessionMelanoma📄🖼️
  43. Abstract LBA4042LBA2026-04-05 · 14:45 CT · S406
    Long-term follow-up of Keytruda 3L+ for metastatic melanoma: KEYNOTE-233
    H. Rugo, M. Reck, S. Peters, et al. · National Cancer Center Japan
    Plenary SessionMelanoma📄🖼️
  44. Abstract 98862026-04-02 · 21:15 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-947 study)
    A. Spira, M. Krop, N. Rizvi · MD Anderson Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  45. Abstract 97602026-04-03 · 16:00 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-347 study)
    M.C. Garassino, S. Modi, L. Paz-Ares · Vall d'Hebron Institute of Oncology
    Poster SessionMelanoma📄🖼️
  46. Abstract 99362026-04-03 · 19:15 CT · Arie Crown Theater
    KEYNOTE-922: Keytruda (pembrolizumab) 2L in metastatic melanoma
    S. Antonia, M.C. Garassino, H. Rugo, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  47. Abstract 97192026-04-01 · 13:30 CT · E450
    Long-term follow-up of Opdivo 3L+ for metastatic melanoma: CheckMate-476
    N. Rizvi, M.C. Garassino, C. Robert, et al. · Karolinska Institute
    Poster SessionMelanoma📄🖼️
  48. Abstract 100522026-04-02 · 19:15 CT · S100A
    CheckMate-549: Opdivo (nivolumab) adjuvant in metastatic melanoma
    R. Herbst, F. Andre, S. Modi · University of Chicago
    Poster SessionMelanoma📄🖼️
  49. Abstract 96952026-04-03 · 15:15 CT · S406
    Long-term follow-up of Opdivo 2L for metastatic melanoma: CheckMate-881
    M.C. Garassino, P. Schmid, N. Rizvi, et al. · Dana-Farber Cancer Institute
    Poster SessionMelanoma📄🖼️
  50. Abstract 97712026-04-03 · 14:15 CT · Arie Crown Theater
    Long-term follow-up of Opdivo neoadjuvant for metastatic melanoma: CheckMate-102
    F. Andre, C. Robert, T. Mok, et al. · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  51. Abstract 99742026-04-02 · 21:15 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-689
    J. Brahmer, L. Paz-Ares, J. Cortes, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionMelanoma📄🖼️
  52. Abstract 97012026-04-02 · 18:00 CT · S406
    CheckMate-164: Opdivo (nivolumab) maintenance in metastatic melanoma
    J. Cortes, H. Borghaei, F. Andre, et al. · Cleveland Clinic
    Poster SessionMelanoma📄🖼️
  53. Abstract 104792026-04-02 · 14:00 CT · S100A
    CheckMate-107: Opdivo (nivolumab) 3L+ in metastatic melanoma
    F. Andre, H. Rugo, H. Borghaei · National Cancer Center Japan
    Poster SessionMelanoma📄🖼️
  54. Abstract LBA4053LBA2026-04-05 · 15:30 CT · S100A
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-521
    S. Antonia, H. Rugo, C. Robert · Chinese University of Hong Kong
    Late-Breaking Oral Abstract SessionMelanoma📄🖼️🎬
  55. Abstract 99102026-04-02 · 14:15 CT · S406
    CheckMate-865: Opdivo (nivolumab) 1L in metastatic melanoma
    P. Schmid, A. Spira, L. Paz-Ares, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionMelanoma📄🖼️
  56. Abstract 101242026-04-01 · 18:45 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-700 study)
    S. Tolaney, N. Rizvi, M.C. Garassino · National Cancer Center Japan
    Oral Abstract SessionMelanoma📄🖼️🎬
  57. Abstract 96862026-04-02 · 18:00 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-104 study)
    R. Herbst, A. Spira, F. Andre, et al. · Cleveland Clinic
    Poster SessionMelanoma📄🖼️
  58. Abstract 95692026-04-05 · 16:45 CT · Hall B1
    Long-term follow-up of Opdivo adjuvant for metastatic melanoma: CheckMate-406
    C. Saura, S. Peters, T. Mok, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  59. Abstract 95182026-04-01 · 21:15 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-557 study)
    M. Reck, J. Brahmer, N. Rizvi, et al. · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  60. Abstract 95352026-04-05 · 14:00 CT · S406
    Long-term follow-up of Opdivo 3L+ for metastatic melanoma: CheckMate-25
    S. Modi, E. Winer, S. Antonia, et al. · Mayo Clinic
    Oral Abstract SessionMelanoma📄🖼️🎬
  61. Abstract 96952026-04-04 · 20:00 CT · S100A
    CheckMate-149: Opdivo (nivolumab) adjuvant in metastatic melanoma
    J. Cortes, M.C. Garassino, L. Paz-Ares · Johns Hopkins Kimmel Cancer Center
    Education SessionMelanoma📄🖼️
  62. Abstract 103892026-04-05 · 20:15 CT · E450
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-114 study)
    J. Cortes, S. Antonia, S. Modi, et al. · Royal Marsden Hospital
    Poster SessionMelanoma📄🖼️
  63. Abstract 96902026-04-04 · 15:00 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-664 study)
    J. Brahmer, S. Antonia, L. Paz-Ares · Mayo Clinic
    Oral Abstract SessionMelanoma📄🖼️🎬
  64. Abstract 104412026-04-03 · 21:30 CT · Arie Crown Theater
    KEYNOTE-557: Keytruda (pembrolizumab) 1L in metastatic melanoma
    S. Modi, A. Spira, S. Tolaney, et al. · Princess Margaret Cancer Centre
    Poster SessionMelanoma📄🖼️
  65. Abstract 102652026-04-04 · 21:30 CT · E450
    KEYNOTE-432: Keytruda (pembrolizumab) 2L in metastatic melanoma
    M. Reck, P. Schmid, M.C. Garassino, et al. · University of Chicago
    Poster SessionMelanoma📄🖼️
  66. Abstract 97502026-04-02 · 21:15 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-640
    C. Robert, M.C. Garassino, R. Herbst, et al. · Cleveland Clinic
    Oral Abstract SessionMelanoma📄🖼️🎬
  67. Abstract 99872026-04-05 · 18:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-530 study)
    T. Mok, L. Paz-Ares · Dana-Farber Cancer Institute
    Poster SessionMelanoma📄🖼️
  68. Abstract LBA4067LBA2026-04-01 · 15:45 CT · Arie Crown Theater
    KEYNOTE-205: Keytruda (pembrolizumab) maintenance in metastatic melanoma
    S. Antonia, M. Reck · Johns Hopkins Kimmel Cancer Center
    Late-Breaking Oral Abstract SessionMelanoma📄🖼️🎬
  69. Abstract 95922026-04-05 · 15:45 CT · Arie Crown Theater
    Long-term follow-up of Opdivo adjuvant for metastatic melanoma: CheckMate-383
    M. Reck, S. Tolaney, F. Andre, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionMelanoma📄🖼️🎬
  70. Abstract e120692026-04-04 · 21:45 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-524 study)
    R. Herbst, C. Saura, J. Brahmer, et al. · Karolinska Institute
    Publication OnlyMelanoma📄🖼️
  71. Abstract 103462026-04-02 · 18:45 CT · E450
    Long-term follow-up of Keytruda 3L+ for metastatic melanoma: KEYNOTE-991
    L. Paz-Ares, H. Rugo, M. Reck · Dana-Farber Cancer Institute
    Poster Discussion SessionMelanoma📄🖼️
  72. Abstract 103072026-04-05 · 15:00 CT · Arie Crown Theater
    CheckMate-617: Opdivo (nivolumab) 1L in metastatic melanoma
    C. Robert, L. Paz-Ares, G. Curigliano, et al. · Karolinska Institute
    Poster Discussion SessionMelanoma📄🖼️
  73. Abstract TPS80722026-04-03 · 21:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-335 study)
    N. Rizvi, G. Curigliano, H. Rugo, et al. · Stanford Cancer Institute
    Trials in Progress Poster SessionMelanoma📄🖼️
  74. Abstract 100552026-04-04 · 18:30 CT · S406
    KEYNOTE-660: Keytruda (pembrolizumab) 3L+ in metastatic melanoma
    R. Herbst, T. Mok · University of Chicago
    Poster SessionMelanoma📄🖼️
  75. Abstract 98862026-04-03 · 21:30 CT · E450
    KEYNOTE-458: Keytruda (pembrolizumab) 1L in metastatic melanoma
    S. Tolaney, F. Andre · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  76. Abstract LBA4075LBA2026-04-03 · 14:30 CT · E450
    KEYNOTE-193: Keytruda (pembrolizumab) adjuvant in metastatic melanoma
    P. Schmid, A. Spira · Memorial Sloan Kettering Cancer Center
    Plenary SessionMelanoma📄🖼️
  77. Abstract 102932026-04-03 · 16:30 CT · E450
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-948 study)
    A. Spira, M. Reck, F. Andre, et al. · National Cancer Center Japan
    Poster SessionMelanoma📄🖼️
  78. Abstract 100792026-04-02 · 13:00 CT · E450
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-48 study)
    L. Paz-Ares, E. Winer, J. Cortes, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionMelanoma📄🖼️
  79. Abstract 104842026-04-05 · 15:45 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-842
    A. Spira, S. Tolaney · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  80. Abstract 100962026-04-04 · 15:00 CT · S100A
    Long-term follow-up of Opdivo 3L+ for metastatic melanoma: CheckMate-474
    S. Tolaney, A. Spira, C. Robert, et al. · Princess Margaret Cancer Centre
    Education SessionMelanoma📄🖼️
  81. Abstract 102262026-04-03 · 19:15 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-658 study)
    P. Schmid, A. Spira, N. Rizvi, et al. · National Cancer Center Japan
    Poster Discussion SessionMelanoma📄🖼️
  82. Abstract 100112026-04-03 · 15:45 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-616 study)
    L. Paz-Ares, A. Spira, S. Peters, et al. · Karolinska Institute
    Poster Discussion SessionMelanoma📄🖼️
  83. Abstract 98102026-04-04 · 15:45 CT · E450
    Long-term follow-up of Keytruda maintenance for metastatic melanoma: KEYNOTE-456
    F. Andre, L. Paz-Ares, S. Peters · Dana-Farber Cancer Institute
    Poster SessionMelanoma📄🖼️
  84. Abstract LBA4083LBA2026-04-04 · 20:15 CT · S406
    CheckMate-794: Opdivo (nivolumab) neoadjuvant in metastatic melanoma
    H. Borghaei, G. Curigliano, F. Andre, et al. · Massachusetts General Hospital
    Late-Breaking Oral Abstract SessionMelanoma📄🖼️🎬
  85. Abstract 95142026-04-03 · 21:30 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 3L+ for metastatic melanoma: KEYNOTE-701
    T. Mok, A. Spira, E. Winer · Karolinska Institute
    Poster SessionMelanoma📄🖼️
  86. Abstract 95562026-04-04 · 19:15 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-608
    S. Antonia, A. Spira, E. Winer · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  87. Abstract 98622026-04-03 · 21:30 CT · Hall B1
    CheckMate-187: Opdivo (nivolumab) neoadjuvant in metastatic melanoma
    A. Spira, M. Krop, G. Curigliano, et al. · Institut Gustave Roussy
    Poster Discussion SessionMelanoma📄🖼️
  88. Abstract TPS80872026-04-03 · 18:30 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-612 study)
    L. Paz-Ares, S. Antonia, G. Curigliano, et al. · Karolinska Institute
    Trials in Progress Poster SessionMelanoma📄🖼️
  89. Abstract 103492026-04-01 · 14:00 CT · Hall B1
    CheckMate-253: Opdivo (nivolumab) adjuvant in metastatic melanoma
    C. Saura, L. Paz-Ares · Massachusetts General Hospital
    Poster Discussion SessionMelanoma📄🖼️
  90. Abstract 104272026-04-04 · 13:45 CT · Arie Crown Theater
    KEYNOTE-816: Keytruda (pembrolizumab) maintenance in metastatic melanoma
    T. Mok, R. Herbst · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionMelanoma📄🖼️
  91. Abstract 100452026-04-03 · 20:00 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-702 study)
    E. Winer, M. Krop · Massachusetts General Hospital
    Poster Discussion SessionMelanoma📄🖼️
  92. Abstract 95572026-04-05 · 21:45 CT · Hall B1
    CheckMate-971: Opdivo (nivolumab) 3L+ in metastatic melanoma
    M.C. Garassino, J. Brahmer · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  93. Abstract 95872026-04-04 · 14:00 CT · S406
    CheckMate-805: Opdivo (nivolumab) 3L+ in metastatic melanoma
    S. Peters, M.C. Garassino, H. Rugo · MD Anderson Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  94. Abstract 96142026-04-04 · 14:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-554 study)
    N. Rizvi, C. Robert, M. Krop · Memorial Sloan Kettering Cancer Center
    Poster SessionMelanoma📄🖼️
  95. Abstract 101052026-04-04 · 19:00 CT · S100A
    Long-term follow-up of Keytruda neoadjuvant for metastatic melanoma: KEYNOTE-63
    P. Schmid, M. Reck, S. Peters · University of Chicago
    Poster SessionMelanoma📄🖼️
  96. Abstract 99192026-04-05 · 19:15 CT · E450
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-818
    M. Krop, C. Saura, S. Antonia, et al. · Institut Gustave Roussy
    Poster Discussion SessionMelanoma📄🖼️
  97. Abstract e120962026-04-01 · 19:00 CT · Arie Crown Theater
    KEYNOTE-869: Keytruda (pembrolizumab) 2L in metastatic melanoma
    H. Rugo, G. Curigliano, M.C. Garassino · National Cancer Center Japan
    Publication OnlyMelanoma📄🖼️
  98. Abstract 95462026-04-02 · 15:30 CT · S406
    CheckMate-178: Opdivo (nivolumab) 2L in metastatic melanoma
    R. Herbst, C. Saura, M. Reck, et al. · MD Anderson Cancer Center
    Oral Abstract SessionMelanoma📄🖼️🎬
  99. Abstract LBA4098LBA2026-04-05 · 19:00 CT · E450
    Long-term follow-up of Keytruda 1L for metastatic melanoma: KEYNOTE-174
    C. Robert, M. Krop, N. Rizvi · National Cancer Center Japan
    Late-Breaking Oral Abstract SessionMelanoma📄🖼️🎬
  100. Abstract 98722026-04-03 · 18:30 CT · S100A
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-376 study)
    S. Tolaney, L. Paz-Ares, R. Herbst · Chinese University of Hong Kong
    Poster Discussion SessionMelanoma📄🖼️
  101. Abstract 98182026-04-05 · 20:45 CT · S100A
    KEYNOTE-111: Keytruda (pembrolizumab) maintenance in metastatic melanoma
    S. Antonia, T. Mok, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  102. Abstract 95852026-04-02 · 15:00 CT · E450
    KEYNOTE-192: Keytruda (pembrolizumab) 3L+ in metastatic melanoma
    S. Peters, R. Herbst · Royal Marsden Hospital
    Poster SessionMelanoma📄🖼️
  103. Abstract 96392026-04-02 · 15:45 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-629
    G. Curigliano, N. Rizvi, S. Peters · Peter MacCallum Cancer Centre
    Clinical Science SymposiumMelanoma📄🖼️
  104. Abstract 99952026-04-04 · 21:15 CT · S100A
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-433 study)
    A. Spira, J. Brahmer, S. Modi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionMelanoma📄🖼️
  105. Abstract 103282026-04-04 · 13:00 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-155
    S. Peters, H. Borghaei, R. Herbst, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionMelanoma📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.